Last Chance 20% Off: Create a free Seeking Alpha account
Join the community and access breaking stock news, subscribe to our leading investing newsletters and follow top analysts. Take advantage of our 20% off sitewide promotion for Black Friday after creating a free account.
EXAS Exact Sciences CorporationStock Price & Overview
Stock Price & Overview
$61.74
EXAS Stock Price
Quant Ranking
EXAS Analysis
EXAS News
Latest Headlines
Ratings Summary
People Also Follow
Similar to EXAS
ETFs Holding EXAS
EXAS Company Profile
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company’s pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXAS Revenue
EXAS Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
EXAS Ownership
EXAS Peers
Risk
Technicals
EXAS Transcripts
Investor Presentations
EXAS SEC Filings
Press Releases
EXAS Income Statement
EXAS Balance Sheet
EXAS Cash Flow Statement
EXAS Long Term Solvency
Discover More
You may be interested in: